Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALPHA COGNITION INC

5.04
-0.0200-0.40%
Post-market: 5.200.1600+3.17%19:40 EDT
Volume:61.85K
Turnover:322.56K
Market Cap:80.74M
PE:-2.50
High:5.55
Open:5.09
Low:5.04
Close:5.06
Loading ...

Company Profile

Company Name:
ALPHA COGNITION INC
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
- -
Office Location:
750 West Pender Street,Suite 1200,Vancouver,British Columbia,Canada
Zip Code:
V6C 2T8
Fax:
- -
Introduction:
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Directors

Name
Position
Len Mertz
Chairman and Director
Michael McFadden
Chief Executive Officer and Director
Kenneth Cawkell
Corporate Secretary and Director
John Havens
Director
Phillip Mertz
Director
Rejeev Bakshi
Director

Shareholders

Name
Position
Michael McFadden
Chief Executive Officer and Director
Lauren D'Angelo
Chief Commercial Officer and Chief Operating Officer
Henry Du
Vice President of Finance and Accounting and interim Chief Financial Officer
Kenneth Cawkell
Corporate Secretary and Director